RICHMOND, Calif., Nov. 24, 2017 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (NASDAQ:SGMO) announced today that the
Compensation Committee of the Company's Board of Directors approved
the grant effective on November 22,
2017 of inducement stock options to purchase a total of
164,000 shares of common stock to four new employees.
The stock options have an exercise price per share equal
to $15.00, the fair market value on the grant
date, November 22, 2017. Each stock option vests over the
course of four years, with 25% vesting on the one-year anniversary
of the grant date and 1/48 of the shares vesting monthly thereafter
so that all of the shares subject to the stock option shall be
vested on the fourth anniversary of the grant date, subject to the
new employee's continued service relationship with the Company on
each such date. Each stock option has a ten year term and is
subject to the terms and conditions of the Company's Amended and
Restated 2013 Stock Incentive Plan and the stock option agreement
pursuant to which the option is granted.
The stock options were granted as an inducement material to the
new employees' entering into employment with Sangamo
Therapeutics in accordance with NASDAQ Listing Rule
5635(c)(4).
About Sangamo Therapeutics
Sangamo Therapeutics, Inc.
is focused on translating ground-breaking science into genomic
therapies that transform patients' lives using the Company's
industry leading platform technologies in genome editing, gene
therapy, gene regulation and cell therapy. For more information
about Sangamo, visit www.sangamo.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-300561350.html
SOURCE Sangamo Therapeutics, Inc.